program. He is the editor of Clinical Trials: Journal of the Society for Clinical Trials and is statistical and associate editor of the Annals of Internal Medicine, since 1987. He served on the Institute of Medicine’s the Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides: Second Biennial Update, Committee to Review the Evidence Regarding the Link between Exposure to Agent Orange and Diabetes, Immunization Safety Review Committee, the Committee on Alternatives to the Daubert Standards, and the Committee on Treatment of Post-traumatic Stress Disorder in Veterans. Dr. Goodman also served on the Surgeon General’s committee to write the 2004 report on the Health Consequences of Smoking. He is a scientific advisor to the Medical Advisory Panel of the National Blue Cross/Blue Shield Technology Evaluation Center, and was appointed to the Methodology Committee of the Patient Centered Outcomes Research Institute. Dr. Goodman received a B.A. from Harvard, an M.D. from New York University, trained in Pediatrics at Washington University in St. Louis, and received an M.H.S. in biostatistics, and Ph.D. in epidemiology from Johns Hopkins University. He writes and teaches on evidence evaluation and inferential, methodologic, and ethical issues in epidemiology and clinical research.

Alasdair Breckenridge, M.D., FRCP, is chairman of the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is the executive agency of the UK Department of Health, which is responsible for protecting and promoting public health and patient safety by ensuring that medicines, health care products, and medical equipment meet appropriate standards of safety, quality, performance, and effectiveness and are used safely. In 2004, he was awarded a knighthood for his services to medicine in recognition of his role in ensuring that British patients receive safe medical treatment. Dr. Breckenridge has played a leading role in monitoring the safety of medicines for many years. He previously was chairman of the UK Committee on the Safety of Medicines (CSM) and was a member of the CSM Adverse Reactions Group and Subcommittee on Adverse Reactions to Vaccines and Immunization. He is a former professor of clinical pharmacology at the University of Liverpool and headed its Department of Pharmacology and Therapeutics for 26 years. Dr. Breckenridge has also been both a member and chairman of a regional health authority and a member of a local health authority. His research interests include the pharmacology of HIV drugs.

Lisa Egbuonu-Davis, M.D., M.P.H., M.B.A., is an executive adviser in Booz Allen Hamilton’s health care practice. Her focus includes business implications of health care reform, strategies to support the product-value proposition from development through commercialization, and practices to ensure compliance and transparency while delivering business impact. Dr. Egbuonu-Davis joined Booz Allen after 18 years in the pharmaceutical industry, including 13 years at Pfizer Pharmaceuticals, where she served as vice president for global outcomes



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement